Blc2 is a prognosticator for IDC
 

The article: http://www.breastcancersource.com/br..._27859___.aspx

The abstract: http://annonc.oxfordjournals.org/cgi...ract/18/6/1004

Of interest:

"Results: In the entire series, the Bcl2 variable was an independent<SUP> </SUP>predictor of clinical outcome, and its prognostic independence<SUP> </SUP>was maintained when lymph node-negative and -positive patients<SUP> </SUP>were considered separately. In this regard, of particular interest<SUP> </SUP>was the observation of a subgroup of node-negative breast cancer<SUP> </SUP>patients with a negative Bcl2 immunostaining, who had a very<SUP> </SUP>high probability of relapse or death (respectively about five<SUP> </SUP>and seven times greater than patients with a positive Bcl2 immunostaining).<SUP> </SUP>Moreover, the Bcl2 variable retained prognostic significance<SUP> </SUP>also in subgroups of patients treated with either adjuvant endocrine<SUP> </SUP>therapy or chemotherapy.<SUP>"</SUP>
<SUP></SUP>
<SUP></SUP>
<SUP>Hopeful</SUP>

Thanks for posting this Hopeful. As most of the articles posted here I don't understand most of them really and have no idea how I would find out half the stuff mentioned in them as it pertains to my particular cancer BUT this article caused me to chuckle anyway. There was a quote by a "team" from the "University of Bologna." LOL LOL LOL! I got a kick out of that.

Have a great day and thanks to everyone who stays on top of this world called breast cancer. You are a blessing to all of us.

Mary Jo

Q 10
 

Co-enzyme Q10 restores the bcl 2 gene to its normal fuction. Search under bcl-2 and Q10.
cheers
jackie